Prognostic value of lymph node ratio and extramural vascular invasion on survival for patients undergoing curative colon cancer resection

C N Parnaby, N W Scott, G Ramsay, C MacKay, L Samuel, G I Murray, M A Loudon, C N Parnaby, N W Scott, G Ramsay, C MacKay, L Samuel, G I Murray, M A Loudon

Abstract

Background: Increasing lymph node ratio (LNR) (ratio of metastatic lymph nodes to the total number of harvested lymph nodes) and extramural vascular invasion (EMVI) have been proposed as adverse prognostic indicators in colorectal cancer, although their use remains variable and controversial. The aim of the present study was to assess the prognostic value of LNR and EMVI in predicting survival for patients undergoing curative colon cancer resection.

Methods: Between 2006 and 2012, 922 patients underwent curative colon cancer resection. Surgical technique and pathological assessment did not change during the study period. Clinical and pathological data were collected from a prospectively maintained database. The primary outcome measure was overall survival and disease-free survival. LNR was separated into five categories based on three previously calculated cutoff values: LNR 0 (no lymph nodes involved), LNR 1 (ratio 0.01<0.17), LNR 2 (ratio 0.18-0.41), LNR 3 (ratio 0.42-0.69), and LNR 4 (ratio >0.70).

Results: Nine hundred and twenty-two patients underwent colon cancer resection. The median follow-up for survivors was 52.8 months (IQR 34.6-77.6). The median total number of lymph nodes harvested was 16 (IQR13-22). On multivariate analysis, both pN and LNR were strongly associated with overall and disease-free survival. Using the Akaike information criterion (AIC), LNR had greater prognostic value compared with pN. For overall survival, compared with patients in LNR category 0, hazard ratios (95% CI) for those in categories 1, 2, 3 and 4 were 1.37 (1.03,1.82), 2.37 (1.70,3.30), 2.40 (1.57,3.65) and 5.51 (3.16,9.58), respectively. For disease-free survival, patients had hazard ratios (95% CI) of 1.78 (1.25,2.52), 3.79 (2.56,5.61), 2.60 (1.50,4.48) and 4.76 (2.21,10.27), respectively. The presence of EMVI was a significant predictor of decreased overall and disease-free survival (P<0.001).

Conclusions: This study demonstrated, in the presence of high surgical, oncology and pathological standards, EMVI and increasing LNR were independent predictors of decreased overall and disease-free survival for patients undergoing curative colon cancer resection. LNR was superior to pN stage in predicting overall and disease-free survival.

Figures

Figure 1
Figure 1
Overall survival by lymph node ratio category (LNR 0–4) for patients undergoing curative colon cancer resection.
Figure 2
Figure 2
Disease-free survival by lymph node ratio category (LNR 0–4) for patients undergoing curative colon cancer resection.
Figure 3
Figure 3
Overall survival of patients with extramural vascular invasion by LNR category (LNR 0, LNR 1 and LNR 2–4 together) undergoing curative colon cancer resection.
Figure 4
Figure 4
Overall survival of patients without extramural vascular invasion by LNR category (LNR 0, LNR 1 and LNR 2–4 together) undergoing curative colon cancer resection.

References

    1. Baxter NN, Ricciardi R, Simunovic M, Urbach DR, Virnig BA. An evaluation of the relationship between lymph node number and staging in pT3 colon cancer using population-based data. Dis Colon Rectum. 2010;53:65–70.
    1. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005;23:8706–8712.
    1. Betge J, Pollheimer MJ, Lindtner RA, Komprat P, Schlemmer A, Rehak P, Vieth M, Hoefler G, Langner C. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer. 2012;118:628–638.
    1. Bhangu A, Fitzgerald JEF, Slesser A, Northover JM, Faiz O, Tekkis P. Prognostic significance of extramural vascular invasion in T4 rectal cancer. Colorectal Dis. 2013;15 (11:e665–e671.
    1. Bui L, Rempel E, Reeson D, Simunovic M. Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol. 2006;93 (6:439–445.
    1. Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg. 2006;244 (4:602–610.
    1. Choi HK, Law WL, Poon JT. The optimal number of lymph nodes examined in stage II colorectal cancer and its impact of on outcomes. BMC Cancer. 2010;10:267.
    1. Cianchi F, Palomba A, Boddi V, Messerini L, Pucciani F, Perigli G, Bechi P, Cortesini C. Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined. World J Surg. 2002;26 (3:384–389.
    1. Courtney ED, West NJ, Kaur C, Ho J, Kalber B, Hagger R, Finlayson C, Leicester RJ. Extramural vascular invasion is an adverse prognostic indicator of survival in patients with colorectal cancer. Colorectal Dis. 2009;11:150–156.
    1. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, Andre T, Hoff PM. Bevacizumab plus oxaliplatin as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225–1233.
    1. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation–technical notes and outcome. Colorectal Dis. 2009;11:354–365.
    1. International Agency for Research on Cancer . World Health Organization: Lyon, France; 2008. GLOBOCAN: Cancer Incidence, Mortality and Prevalence Worldwide (2008 Estimates)
    1. Lykke J, Roikjaer O, Jess P, Danish Colorectal Cancer Group The relation between lymph node status and survival in stage I-III colon cancer: results from a prospective nationwide cohort study. Colorectal Dis. 2013;15:559–565.
    1. Morris M, Platell C, de Boer B, McCaul K, Iacopetta B. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg. 2006;93:866–871.
    1. Moug SJ, McColl G, Lloyd SM, Wilson G, Saldanha JD, Diament RH. Comparison of positive lymph node ratio with an inflammation-based prognostic score in colorectal cancer. Br J Surg. 2011;98:282–286.
    1. O'Shea A, Aly O, Parnaby CN, Loudon MA, Samuel LM, Murray GI. Increased lymph node yield in colorectal cancer is not necessarily associated with greater number of lymph node positive cancers. PLoS One. 2014;9:e104991.
    1. Quirke P, Morris E. Reporting colorectal cancer. Histopathology. 2007;50:103–112.
    1. Rosenberg R, Engel J, Bruns C, Hettland W, Hermes N, Jauch KW, Kopp R, Putterich E, Ruppert R, Schuster T, Friess H, Hulzel D. The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann Surg. 2010;251:1070–1078.
    1. Rosenberg R, Friederichs J, Schuster T, Gertler R, Maak M, Becker K, Grebner A, Ulm K, Hofler H, Nekarda H, Siewert JR. Prognosis of patients with colorectal cancer is associated with lymph node ratio. Ann Surg. 2008;248:1067–1073.
    1. Schiffmann L, Eiken AK, Gock M, Klar E. Is the lymph node ratio superior to the Union for International Cancer Control (UICC) TNM in prognosis of colon cancer. World J Surg Oncol. 2013;11:79.
    1. SCOT-Short Course Oncology Therapy 2007SCOT—Short Course Oncology Therapy: a study of adjuvant chemotherapy in colorectal cancer by the CACTUS and QUASAR 3 groupsClinical number NCT00749450.
    1. Sjo OH, Merok MA, Svindland A, Nesbakken A. Prognostic impact of lymph node harvest and lymph node ratio in patients with colon cancer. Dis Colon Rectum. 2012;55:307–315.
    1. Sobin LH, Wittekind Ch.(eds) (1997TNM Classification of Malignant Tumours5th ednWiley-Liss: New York, NY, USA
    1. Sternberg A, Sibirsky O, Cohen D, Blemenson LE, Rodriguez-Bigas MA, Petrelli NJ. New approach to the substaging of node-positive colorectal adenocarcinoma. Ann Surg Oncol. 1999;6:161–165.
    1. Ueno H, Mochizuki H, Akagi Y, Kusumi T, Yamada K, Ikegami M, Kawachi H, Kameoka S, Ohkura Y, Masaki T, Kushima R, Takahashi K, Ajioka Y, Hase K, Ochiai A, Wada R, Iwaya K, Shimazaki H, Nakamura T, Sugihara K. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol. 2012;30:1519–1526.
    1. Wang J, Hassett JM, Dayton MT, Kulaylat MN. Lymph node ratio: role in the staging of node-positive colon cancer. Ann Surg Oncol. 2008;15:1600–1608.
    1. Williams GT, Quirke P, Shepherd NA.2007Standards and Datasets for Reporting Cancers. Dataset for Colorectal Cancer2nd ednRoyal College of Pathologists: London, UK

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit